Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL3308504 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL2399914 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1614041 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Dodecane SCHEMBL1747351 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1190938 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL9107982 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL11904142 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL276236 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1680974 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Hexadecane SCHEMBL3291441 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023189319-A1 | AMINO COMPOUND, POLYAMIDE ACID AND POLYIMIDE USING SAID AMINO COMPOUND, AND METHOD FOR PRODUCING SAME | 日鉄ケミカル＆マテリアル株式会社 | 2023-10-05 | — | — | WO | disclosed |
| EP-4213883-A1 | OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS | Astrazeneca AB (SE) | 2023-07-26 | — | — | EP | disclosed |
| US-11675267-B2 | Resist composition and method for producing resist pattern | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-06-13 | — | — | US | disclosed |
| CN-116133691-A | Oligonucleotides conjugated to fatty acids | 阿斯利康(瑞典)有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
| CN-115286559-A | Preparation method of anti-new crown drug Parovirid key intermediate | 上海再启生物技术有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-109415283-B | Compound having naphthalene ring, liquid crystal composition, and liquid crystal display element | 捷恩智株式会社 | 2022-04-12 | — | — | CN | disclosed |
| US-20210311392-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-10-07 | — | — | US | disclosed |
| CN-109705124-B | Radioactive fluorine labeled Larotrectinib compound and preparation method thereof | 上海健康医学院 | 2021-09-24 | — | — | CN | disclosed |
| EP-1265867-A1 | NOVEL MALONIC ACID DERIVATES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-12-18 | — | — | EP | disclosed |
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062735-A1 | NOVEL MALONIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS INHIBITOR OF FACTOR XA ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1127884-A1 | Novel malonic acid derivatives, processes for their preparation, their use as inhibitor of factor XA activity and pharmaceutical compositions containing them | Aventis Pharma Deutschland GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| US-6251917-B1 | Benzamidoaldehydes and their use as cysteine protease inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| US-6045720-A | EXHIBITS A FERROELECTRIC LIQUID CRYSTALLINE PHASE AND AN ANTIFERROELECTRIC LIQUID CRYSTALLINE PHASE BY ITSELF; HIGH SPEED RESPONSE; DISPLAY ELEMENT; OPTICAL SWITCHING ELEMENT; | CHISSO CORPORATION (JP) | 2000-04-04 | — | — | US | disclosed |
| CN-1238761-A | benzamide aldehydes and their use as cysteine protease inhibitors | BASF AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| EP-0926216-A1 | Organic electroluminescent device using a triarylamine derivative | CHISSO CORPORATION (JP) | 1999-06-30 | — | — | EP | disclosed |
| US-5608069-A | TREATMENT OF NERVOUS SYSTEM DISORDERS WITH GAMMA-AMINOBUTYRIC ACID | NOVO NORDISK A/S (DK) | 1997-03-04 | — | — | US | disclosed |
| CN-1128990-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK AS (DK) | 1996-08-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022596-A1 | Novel malonic acid derivatives, processes for their preparation their use and pharmaceutical compositions containing them | F12, ME1, F11 | ALDH1A1 129/4885LMNA 1644/4885HSD17B10 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.